SNGX vs. LSTA, CGTX, CVM, INKT, KALA, MRNS, UBX, DARE, VRCA, and MTEX
Should you be buying Soligenix stock or one of its competitors? The main competitors of Soligenix include Lisata Therapeutics (LSTA), Cognition Therapeutics (CGTX), CEL-SCI (CVM), MiNK Therapeutics (INKT), KALA BIO (KALA), Marinus Pharmaceuticals (MRNS), Unity Biotechnology (UBX), Daré Bioscience (DARE), Verrica Pharmaceuticals (VRCA), and Mannatech (MTEX). These companies are all part of the "pharmaceutical products" industry.
Soligenix vs.
Soligenix (NASDAQ:SNGX) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability, dividends and community ranking.
Soligenix has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500.
In the previous week, Soligenix had 4 more articles in the media than Lisata Therapeutics. MarketBeat recorded 5 mentions for Soligenix and 1 mentions for Lisata Therapeutics. Soligenix's average media sentiment score of 0.30 beat Lisata Therapeutics' score of 0.00 indicating that Soligenix is being referred to more favorably in the media.
3.6% of Soligenix shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 2.8% of Soligenix shares are held by insiders. Comparatively, 9.1% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Lisata Therapeutics has a net margin of 0.00% compared to Soligenix's net margin of -1,473.38%. Lisata Therapeutics' return on equity of -51.19% beat Soligenix's return on equity.
Soligenix received 264 more outperform votes than Lisata Therapeutics when rated by MarketBeat users. However, 93.33% of users gave Lisata Therapeutics an outperform vote while only 72.97% of users gave Soligenix an outperform vote.
Lisata Therapeutics has a consensus target price of $15.00, suggesting a potential upside of 304.31%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Lisata Therapeutics is more favorable than Soligenix.
Soligenix has higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.
Summary
Lisata Therapeutics beats Soligenix on 10 of the 17 factors compared between the two stocks.
Get Soligenix News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Soligenix Competitors List
Related Companies and Tools
This page (NASDAQ:SNGX) was last updated on 1/21/2025 by MarketBeat.com Staff
